Cost Considerations in the Management of Cancer in the Older Patient
Cost Considerations in the Management of Cancer in the Older Patient
Patients aged 65 years and older represent 12% of the US population yet account for approximately 56% of cancer cases and 69% of all cancer mortalities. The overall cost of cancer in 2005 was $209.9 billion—$74 billion for direct medical costs and $118.4 billion for indirect mortality costs. This paper considers the direct, indirect, and out-of-pocket expenditures incurred by cancer patients ‚â• 50 years of age. Several major empirical studies on supportive care for older patients and cancer-related costs were reviewed. Insurance coverage, hematologic malignancies, squamous cell carcinoma of the head and neck, and cancers of the breast, prostate, colorectum, and lung were evaluated. Major sources of direct medical expenditures covered by third-party insurers for patients aged 65 years and older include extended length of hospital stay, home health assistance following hospital discharge, adjuvant prescription medications, lower-risk treatment (for prostate cancer), and advent of new pharmaceuticals (for colorectal cancer). The mean total direct medical cost for breast cancer is $35,164, and the cumulative cost for prostate cancer is $42,570. Emerging targeted cancer drug costs range from $20,000 to $50,000 annually per patient. Additional clinical trials and cost-effective treatments are needed for older patients to ameliorate the disproportionate economic burden among older individuals with cancer. Additional research about cancer costs may also lead to reforms in cancer care reimbursement, and therefore provide access to affordable health care for older patients.
The overall cost of cancer in 2005 was $209.9 billion: $74 billion for direct medical costs (prevention, screening, diagnosis, treatment, and palliation) and $118.4 billion for indirect mortality costs.[1-3] (Indirect mortality cost refers to the cost of lost productivity due to premature death, with "premature" indicating the difference in life expectancies at given ages of individuals with and without the disease.) Medicare or private health insurance programs cover approximately one-third of cancer-related costs. Non-reimbursed or "out-of-pocket" costs constitute the remaining two-thirds.
The most costly cancers for men are prostate, lung, and colorectal cancers, with the corollary in women being breast, colorectal, and lung cancers. Seniors aged 65 years and over represent 12% of the population in the United States, but account for approximately 56% of cancer cases. This disparity is due, in part, to the increased prevalence of cancer as people age and the high rate of comorbid medical illnesses in older individuals. Care for older individuals may require complex protocols that are likely to be costly, and choice of therapy may also be restricted relative to toxicity of the agent and expected years of life remaining.[5,6] Insurance helps, but patients are bearing a growing portion of these expenditures and may face financial hardships as a result of nonreimbursed cancer costs.
This paper provides an overview of several prominent articles and empirical studies on supportive care and cancer-related costs faced by older cancer patients. It focuses primarily on individuals 65 years of age and over (and where cost information was availble, also considers those aged 50 to 64) and reviews several types of cancer. We consider direct, indirect and out-of-pocket expenditures in this discussion.
Americans 65 years of age and older currently account for more than 13% of the US population. Based on current projections by the US Bureau of Census, by 2030, one in five Americans will be over 65 years of age, reflecting 20.1% of the total population (70.2 million persons). The oldest old-Americans age 85 and older—represent the fastest-growing segment of the US population, with more than 50,000 Americans having reached 100 years of age or more. Attendant to this unprecedented aging explosion is the increased incidence of cancer. The cancer burden of the elderly is high in the United States and has increased over time, with 60% of all malignant tumors occurring among persons aged 65 years and older.
Access to Affordable Cancer Care
A recent study of various cancer types found that fewer than 4% of patients were uninsured at the time they were considered for initial treatment, 48% had private insurance or HMO coverage, 16.8% had Medicare but no supplemental insurance, and 7.5% of patients had Medicaid insurance. Most but not all individuals with health insurance have at least some level of coverage for pharmaceuticals. Because of coverage gaps, deductible requirements, and copayments, out-of-pocket expenditures may be large for cancer patients. Recent technologic developments have also affected costs. These include the advent of targeted drugs and other high-tech therapy (Table 1).[4,11-14] Furthermore, while Medicare Part D might reduce the costs faced by some Medicare beneficiaries, it does not necessarily do so for cancer patients who require costly chemotherapy.
Physiologic Changes of Aging
Aging patients present with comorbidities, such as hypertension, diabetes mellitus, osteoporosis, and osteoarthritis. Certain physiologic changes of aging (decreased renal function, impaired hepatic Blood flow, and decreased cardiac reserve, among others) along with pathologic changes combine to effectuate a decrease in the functional status of the elderly cancer patient and to render cancer care in the elderly more expensive over time. Furthermore, elderly patients with cancer who are contemplating surgical treatment and/or chemotherapy will often require more preoperative studies and laboratory tests in an effort to minimize their risks from potentially toxic treatment, thus increasing costs of cancer care.
Many cancer drugs are metabolized by the liver and can fall prey to specific physiologic changes that are attendant to aging. Liver Blood flow decreases by 0.3% to 1.5 % per year; liver size also decreases, and liver function sees a decrement of 25% to 30%. Decreases in hepatic Blood flow lead to increases in serum drug levels and drug half-lives for drugs in phase I hepatic metabolism. This can result in decreased clearance and increased toxicity with the administration of commonly used chemotherapy drugs. Despite the impact of physiologic changes in the elderly that might negatively impact cancer treatment, improvements in supportive care over the last 10 to 20 years have enabled physicians to offer more aggressive, and often costly, treatments to older patients. Particularly, improvements in antiemetic therapy and mucositis prevention have facilitated the administration of cytotoxic therapies to older patients. Older patients are also at higher risk for bone marrow suppression during chemotherapy, and the aggressive use of granulocyte and erythrocyte growth factors in the course of chemotherapy has lessened the risk of severe neutropenia or anemia in the older patient during therapy.[15,16] New mucositis prevention protocols, intensive care unit monitoring, and the introduction of lower-intensity chemotherapy preparation regimens have made allogeneic transplant a possibility in some patients as old as 80 years.